&lt;p&gt;Predicting the One-Year Prognosis and Mortality of Patients with Acute Ischemic Stroke Using Red Blood Cell Distribution Width Before Intravenous Thrombolysis&lt;/p&gt;

Ye, Weiyi; Li, Jia; Li, Xiang; Yang, Xiangdong; Weng, Yiyun; Xiang, Weiwei; Zhang, Ou; Ke, Boxi; Zhang, Xu

doi:10.2147/cia.s233701

Cited by 19 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, RDW may be utilized as a prognostic biomarker for the prediction of functional outcomes and survival in patients with acute ischemic stroke. Moreover, Ye et al [ 52 ] concluded that the baseline assessment of RDW was positively correlated with the one-year mortality risk in patients with acute ischemic stroke who were treated with intravenous thrombolysis (IVT), thus indicating a potential role of RDW as an independent biomarker of all-cause death during the first year in stroke patients after IVT. Unlike mortality risk, a significant association between RDW levels and functional outcome in stroke patients undergoing IVT was not demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Stroke and Emerging Blood Biomarkers: A Clinical Prospective

Gkantzios

Tsiptsios

Karatzetzou

et al. 2022

Neurology International

View full text Add to dashboard Cite

Stroke constitutes the primary source of adult functional disability, exhibiting a paramount socioeconomic burden. Thus, it is of great importance that the prediction of stroke outcome be both prompt and accurate. Although modern neuroimaging and neurophysiological techniques are accessible, easily available blood biomarkers reflecting underlying stroke-related pathophysiological processes, including glial and/or neuronal death, neuroendocrine responses, inflammation, increased oxidative stress, blood–brain barrier disruption, endothelial dysfunction, and hemostasis, are required in order to facilitate stroke prognosis. A literature search of two databases (MEDLINE and Science Direct) was conducted in order to trace all relevant studies published between 1 January 2010 and 31 December 2021 that focused on the clinical utility of brain natriuretic peptide, glial fibrillary acidic protein, the red cell distribution width, the neutrophil-to-lymphocyte ratio, matrix metalloproteinase-9, and aquaporin-4 as prognostic tools in stroke survivors. Only full-text articles published in English were included. Twenty-eight articles were identified and are included in this review. All studied blood-derived biomarkers proved to be valuable prognostic tools poststroke, the clinical implementation of which may accurately predict the survivors’ functional outcomes, thus significantly enhancing the rehabilitation efficiency of stroke patients. Along with already utilized clinical, neurophysiological, and neuroimaging biomarkers, a blood-derived multi-biomarker panel is proposed as a reasonable approach to enhance the predictive power of stroke prognostic models.

show abstract

Section: Discussionmentioning

confidence: 99%

Stroke and Emerging Blood Biomarkers: A Clinical Prospective

Gkantzios

Tsiptsios

Karatzetzou

et al. 2022

Neurology International

View full text Add to dashboard Cite

show abstract

“…By contrast, Shahsavarinia et al [ 25 ] reported that the baseline RDW did not correlate with outcome after a 3-month follow-up in patients who received tPA treatment. Ye et al [ 26 ] found that RDW was not associated with clinical outcome after 1 year but was significantly related to all-cause mortality.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of red blood cell distribution width in predicting 3-month functional outcome of patients undergoing thrombolysis treatment for acute ischemic stroke

et al. 2021

View full text Add to dashboard Cite

This study was performed to determine whether red blood cell distribution width (RDW) is associated with 3-month poor functional outcome in patients undergoing thrombolytic therapy for acute ischemic stroke. RDW was measured in patients with thrombolytic therapy in emergency department. Functional outcome was assessed after 3 months and poor functional outcome was defined as modified Rankin scale 3 to 6. A total of 240 patients were enrolled, and 82 (34.2%) had a poor functional outcome. The median RDW was significantly elevated in patients with a poor functional outcome compare with those with a good outcome. RDW was independently associated with a 3-month poor functional outcome (odds ratio 3.369, 95% confidence interval 2.214–5.125). The optimal RDW cutoff for predicting 3-month poor functional outcome was 12.8%, and the area under the curve for RDW was 0.818 (95% confidence interval 0.761–0.876). The area under the curve for RDW was higher in male patients than in female patients. The RDW correlated positively with the modified Rankin scale score after 3 months and the initial National Institutes of Health Stroke Scale score. Initial higher RDW level is related to a 3-month poor functional outcome in patients undergoing thrombolytic therapy for acute ischemic stroke.

show abstract

“…RDW-CV is also strongly associated with the incidence of stroke and myocardial infarction (MI) [ 11 ]. Furthermore, it seems to be a reliable and independent predictor of mortality in coronary artery disease (CAD) and ischemic stroke [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Red Blood Cell Distribution Width as a 5-Year Prognostic Marker in Patients Submitted to Carotid Endarterectomy

Gamas

Jácome

Fragão-Marques

et al. 2020

Cerebrovasc Dis Extra

View full text Add to dashboard Cite

Objective: Patients submitted to carotid artery endarterectomy (CEA) have a long-term risk of major adverse cardiovascular events (MACE) of 6–9% at 2 years. Hematological parameters have been shown to have a predictive function in atherosclerotic diseases, namely the red blood cell distribution width-coefficient of variation (RDW-CV). This parameter has been associated with worse outcomes such as myocardial infarction (MI), stroke, and all-cause mortality. This study aims to evaluate the potential role of preoperative hematologic parameters such as RDW-CV in predicting perioperative and long-term cardiovascular adverse events and mortality in patients submitted to CEA. Methods: From January 2012 to January 2019, 180 patients who underwent CEA with regional anesthesia in a tertiary care and referral center were selected from a prospective cohort database. Blood samples were collected preoperatively 2 weeks before admission, including a full blood count. The primary outcome included long-term MACE. Secondary outcomes included all-cause mortality, stroke, MI, acute heart failure, and major adverse limb events (MALE). Results: At baseline, 27.2% of patients had increased RDW-CV. Increased RDW-CV was independently associated with baseline hemoglobin (adjusted odds ratio [aOR] 0.715, 95% CI 0.588–0.869, p = 0.001) and atrial fibrillation (aOR 4.028, 95% CI 1.037–15.639, p = 0.001). After a median follow-up of 50 months, log-rank univariate analysis of RDW-CV demonstrated a significant association between increased RDW-CV and long-term all-cause mortality (log-rank <0.001), MACE (log-rank <0.001), and MI (log-rank = 0.017). After multivariate Cox regression analysis, increased RDW-CV was associated with increased long-term mortality (adjusted hazard ratio [aHR] 2.455, 95% CI 1.231–4.894, p = 0.011) and MACE (aHR 2.047, 95% CI 1.202–3.487, p = 0.008). A decreased hemoglobin to platelet ratio (aHR 2.650e–8, 95% CI 9.049e–15 to 0.078, p = 0.019) was also associated with all-cause mortality. Conclusion: RDW is a widely available and low-cost marker that independently predicts long-term mortality, MACE, and MI after CEA. This biomarker could prove useful in assessing which patients would likely benefit from CEA in the long term.

show abstract

<p>Predicting the One-Year Prognosis and Mortality of Patients with Acute Ischemic Stroke Using Red Blood Cell Distribution Width Before Intravenous Thrombolysis</p>

Cited by 19 publications

References 41 publications

Stroke and Emerging Blood Biomarkers: A Clinical Prospective

Stroke and Emerging Blood Biomarkers: A Clinical Prospective

Prognostic value of red blood cell distribution width in predicting 3-month functional outcome of patients undergoing thrombolysis treatment for acute ischemic stroke

Red Blood Cell Distribution Width as a 5-Year Prognostic Marker in Patients Submitted to Carotid Endarterectomy

Contact Info

Product

Resources

About